In today’s briefing:
- Boryung Pharmaceutical (003850 KS): Focus on Prescription Drugs for Stability and Accelerated Growth
Boryung Pharmaceutical (003850 KS): Focus on Prescription Drugs for Stability and Accelerated Growth
- Boryung Pharmaceutical (003850 KS) aims to achieve a revenue CAGR of 10.9% during 2022–2026 (from 7.8% in 2017–2021) through a chronic disease-focused prescription drug portfolio.
- While hypertension and dyslipidemia drugs remain its cash cow, Boryung has identified oncology and CNS as its new growth engine to achieve KRW1 trillion revenue in 2026.
- Driven by a 28% y/y growth in prescription drug revenue, Boryung has reported record high quarterly sales and operating profit in Q1 2022. The company is continuously launching new drugs.
Before it’s here, it’s on Smartkarma
